World
CONTACTStaffCAREER OPPORTUNITIESADVERTISE WITH USPRIVACY POLICYPRIVACY PREFERENCESTERMS OF USELEGAL NOTICE
© 2024 Pride Publishing Inc.
All Rights reserved
All Rights reserved
By continuing to use our site, you agree to our Private Policy and Terms of Use.
FDA approves Fuzeon
The Food and Drug Administration on Thursday approved Roche and Trimeris's HIV entry inhibitor Fuzeon, making the drug the first entry inhibitor ever to hit the U.S. market. Trimeris and Roche officials say they plan to begin shipping Fuzeon in late March or early April. The FDA based its approval on an analysis of six months of data from two ongoing clinical trials of Fuzeon involving about 1,000 patients who were experiencing resistance to other anti-HIV medications. The data from this analysis showed that the addition of Fuzeon to a combination of other antiretroviral medications reduced blood-based HIV viral loads.
AIDS activists, however, are anxiously awaiting final word from the drug companies on the cost of the medication. The recent announcement that the drug will cost more than $20,000 per patient per year in Europe has U.S. health care providers and HIV-positive people concerned that the U.S. price will make the drug unaffordable for many low-income, uninsured, or underinsured patients. The expected high cost of the drug also may keep Medicaid programs and state-managed AIDS Drug Assistance Programs from covering it. "We don't think we can add Fuzeon [to our drug list] without cutting something else," Michael Montgomery, head of California's ADAP, told The [Raleigh, N.C.] News & Observer. "We are excited about the drug, but we aren't sure we can afford it." The drug developers say the high cost of the medication is due to its difficult manufacturing process.
Fuzeon, previously known as T-20, is the world's first HIV entry inhibitor. The drug works by preventing HIV from being able to attach to receptors on the surface of T cells, thereby preventing infection. All other existing HIV drugs work by interfering with HIV replication in cells already infected with the virus. The injectable medication was designed as a treatment for patients who have failed other anti-HIV regimens. A Fuzeon follow-up product, called T-1249, is currently in development and has been shown in clinical trials to reduce viral levels in patients who have developed resistance to other anti-HIV medications, including Fuzeon.
Want more breaking equality news & trending entertainment stories?
Check out our NEW 24/7 streaming service: the Advocate Channel!
Download the Advocate Channel App for your mobile phone and your favorite streaming device!
From our Sponsors
Most Popular
Here Are Our 2024 Election Predictions. Will They Come True?
November 07 2023 1:46 PM
Meet all 37 of the queer women in this season's WNBA
April 17 2024 11:24 AM
17 Celebs Who Are Out & Proud of Their Trans & Nonbinary Kids
November 30 2023 10:41 AM
Here Are the 15 Most LGBTQ-Friendly Cities in the U.S.
November 01 2023 5:09 PM
Which State Is the Queerest? These Are the States With the Most LGBTQ+ People
December 11 2023 10:00 AM
These 27 Senate Hearing Room Gay Sex Jokes Are Truly Exquisite
December 17 2023 3:33 PM
10 Cheeky and Homoerotic Photos From Bob Mizer's Nude Films
November 18 2023 10:05 PM
42 Flaming Hot Photos From 2024's Australian Firefighters Calendar
November 10 2023 6:08 PM
These Are the 5 States With the Smallest Percentage of LGBTQ+ People
December 13 2023 9:15 AM
Here are the 15 gayest travel destinations in the world: report
March 26 2024 9:23 AM
Watch Now: The Daily
Trending stories from our video partner Advocate Channel.
For more videos and shows go to advocatechannel.com.
Trending stories from our video partner Advocate Channel.
For more videos and shows go to advocatechannel.com.
Latest Stories
Over 90% of trans youth live in states pushing anti-trans legislation: report
April 23 2024 10:08 PM
George Santos pulls out of New York congressional race
April 23 2024 7:04 PM
Biden will hammer Trump over abortion bans in Florida speech
April 23 2024 5:00 AM
Tristan Snell, who brought down Trump University, sees conviction in hush money case
April 22 2024 7:36 PM
Joe Biden admin marks Earth Day with major environmental initiatives
April 22 2024 4:18 PM
Texas Gov. Greg Abbott: 'We want to end' trans and gender nonconforming teachers
April 22 2024 4:13 PM
Nonbinary 17-year-old killed two years after being reported missing
April 22 2024 3:46 PM